Pacira Sells iovera Cold Therapy Device to Zimmer Biomet for $140m
PCRX•Pacira will receive $140m upfront from Zimmer Biomet for its iovera cold therapy nerve treatment device, transferring global IP and commercialization rights. This divestiture is slated to strengthen Pacira’s cash position and enable additional investment in its core non-opioid analgesics business.
1. Deal Structure
Pacira and Zimmer Biomet finalized a $140m all-cash agreement for the iovera focused cold therapy system, transferring patents, manufacturing rights and global commercial obligations. Zimmer Biomet assumes responsibility for ongoing production, regulatory filings and sales activities immediately upon closing.
2. Impact on Pacira
The $140m influx boosts Pacira’s liquidity, allowing the company to redeploy capital toward its non-opioid analgesic portfolio and R&D pipeline. Management expects enhanced financial flexibility and streamlined operations following the divestiture.
3. Zimmer Biomet Commercialization
Zimmer Biomet will integrate iovera into its pain management offerings, leveraging its established sales channels and global footprint to drive adoption. The device is expected to complement Zimmer Biomet’s orthopedic portfolio and support cross-selling opportunities.
